Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
, 24, 6517-6524

Effect of Phacoemulsification on Visual Acuity and Macular Morphology in Patients With Wet Age-Related Macular Degeneration

Affiliations
Randomized Controlled Trial

Effect of Phacoemulsification on Visual Acuity and Macular Morphology in Patients With Wet Age-Related Macular Degeneration

Małgorzata Figurska et al. Med Sci Monit.

Abstract

BACKGROUND This article discusses the effectiveness of phacoemulsification cataract surgery with intraocular lens implantation in patients with wet age-related macular degeneration in the inactive phase of the disease. MATERIAL AND METHODS Forty-nine patients (50 eyes) aged 78.94±5.54 years, previously treated with intravitreal injections of anti-vascular endothelial growth factor agents, were qualified for a prospective, randomized 12-month study. The participants were divided into 2 groups. Group I consisted of 25 patients (25 eyes) who were subjected to phacoemulsification cataract surgery. Group II consisted of 24 patients (25 eyes) who were not subjected to phacoemulsification cataract surgery despite having a lens opacity of grade II or higher according to the Lens Opacities Classification System. RESULTS After 12 months of follow-up, patients in group I gained on average 8.04 letters (p<0.001). Furthermore, 20% of the eyes had a significant improvement in best corrected visual acuity of ≥15 Early Treatment of Diabetic Retinopathy Study Chart letters. Patients in group II lost on average 1.96 letters (p>0.05). No significant differences between central retinal thickness values in either group (p>0.05) were noted. The mean number of intravitreal injections of anti-vascular endothelial growth factor agents during the study was 2.64±1.98 in group I and 2.92±2.40 in group II (p>0.05). CONCLUSIONS Phacoemulsification performed in eyes with wet age-related macular degeneration during the inactive phase of the disease significantly improves visual acuity. In addition, it does not significantly influence the frequency of intravitreal injections of anti-vascular endothelial growth factor agents or disease activity.

Figures

Figure 1
Figure 1
Comparison of changes in the mean value of ETDRS letters gained between group I and group II. The y-axis represents the average number of ETDRS letters gained.
Figure 2
Figure 2
Calculated materiality levels between the mean output BCVA (in the number of ETDRS letters) and averages obtained at subsequent intervals (ANOVA/Bonferroni test). Group I deep-blue curve, group II light-blue curve.
Figure 3
Figure 3
Calculated materiality levels between the mean output CRT in μm and the changes over time (ANOVA/Bonferroni test). Group I deep-blue curve, group II light-lbue curve.
Figure 4
Figure 4
Comparison of the average number of injections in the period before inclusion with the average number of injections during group I observations (t=3.73; p<0.05).
Figure 5
Figure 5
Comparison of the average number of injections in the period before inclusion with the average number of injections during group II observations (t=2.16; p<0.05).

Similar articles

See all similar articles

References

    1. WHO 2011. World Health Organization. Magnitude and causes of visual impairment. Fact Sheet No 82. [accessed 22 November 2011]. 2011. Oct, Available from: URL: http://www.who.int/mediacentre/factsheets/fs282/en/index.html.
    1. Casparis H, Lindsley K, Kuo IC, et al. Surgery for cataracts in people with age-related macular degeneration. Cochrane Database Syst Rev. 2012;6:CD006757. - PMC - PubMed
    1. Kruk J, Kubasik-Kladna K, Aboul-Enein HY. The role oxidative stress in the pathogenesis of eye diseases: Current status and a dual role of physical activity. Mini Rev Med Chem. 2015;16:241–57. - PubMed
    1. Ung L, Pattamatta U, Carnt N, et al. Oxidative stress and reactive oxygen species: A review of their role in ocular disease. Clin Sci (Lond) 2017;131:2865–83. - PubMed
    1. Usui T, Ishida S, Yamashiro K, et al. VEGF164(165) as the pathological isoform: Differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci. 2004;45:368–74. - PubMed

Publication types

Substances

Feedback